$FURY

Fury Reports Intercept of 7.0 g/t Gold over 21.0 Metres at Eau Claire and Mobilizes Third Drill Rig

Fury Gold Mines reported assay results from 8 holes (5,064 m) in its Phase 2 drilling at the Eau Claire gold project in Northern Quebec. Conversion hole 26EC-115 returned 7.01 g/t gold over 21.0 m, including 10.27 g/t over 11.0 m. Fury also mobilized a third drill rig and plans further follow-up.

Original reporting
Published Jul 13, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 13, 2026, 12:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Fury Reports Intercept of 7.0 g/t Gold over 21.0 Metres at Eau Claire and Mobilizes Third Drill Rig — source image
Decision brief

The 30-second read

$FURYBullishMed
01

Why it matters

The company highlights a best-ever intercept (26EC-115) and adds a third diamond drill rig to maintain pace and follow up on the high-grade shoot, implying near-term catalysts from subsequent assay batches.

02

Market read

Traders may view the new high-grade intercept and increased drilling capacity as incremental positive evidence for resource quality, with the next decision point being subsequent assay batches and any updated resource conversion metrics.

03

What to watch

The release includes partial results for one hole and does not provide updated resource estimates or prefeasibility milestones, which may cap immediate re-rating.

Relevance 7/10Novelty 6/10Timing: today’s assay batch and third-rig mobilization for the ongoing Phase 2 program

Background

Fury is running a Phase 2 drill program (15,000 to 25,000 m) at the Eau Claire gold project in Northern Quebec to convert inferred resources to higher-confidence categories and expand the indicated resource.

Company-level read

Ticker impact

$FURYBullishMedium confidence
Context

Fury reported a best-ever Eau Claire intercept, including 7.01 g/t gold over 21.0 m in hole 26EC-115, and mobilized a third rig.

Expected impact

Likely positive bias for FURY shares, with follow-through dependent on additional assay batches and continued continuity.

Evidence & confidence

The release is a primary disclosure of new assay results and an operational step-up (third rig) tied to the same sector being tested, which can re-rate exploration value expectations.

Market effects

Supports sentiment for Canadian gold exploration names, especially those advancing resource conversion with high-grade intercepts.

Reinforces ongoing exploration activity in Northern Quebec’s James Bay region, though impact is likely company-specific.

Limited direct macro linkage; primarily affects company-specific perceived resource quality and optionality.

Counterpoint

High-grade intercepts are encouraging but still within inferred resource conversion work, so investors may discount until more complete, higher-confidence drilling confirms continuity.

Key entities

  • Fury Gold Mines Limited

    Announced assay results from Eau Claire Phase 2 drilling and mobilized a third drill rig.

  • Eau Claire gold project

    Northern Quebec project where the reported high-grade intercepts were drilled.

  • Phase 2 drill program

    Resource conversion and expansion drilling initiative at Eau Claire.

Related articles

$FURYMedAI 8/10

Fury Reports 7.86 g/t Gold Over 9.43 Metres in Infill Drilling at the Eau Claire Gold Project, Quebec

Fury Gold Mines reported final Phase 1 assay results from its 13,000-m drill program and initial Phase 2 results at the Eau Claire gold project in Quebec. Phase 1 completed 21 holes (12,700 m). Key intercepts included 7.86 g/t Au over 9.43 m (26EC-103) and 13.83 g/t over 1.97 m (26EC-102). Phase 2 is ongoing with 14 holes (~7,100 m) and assays available for 720 m.

$ABBVMed

AbbVie inks $757m migraine-focused deal with Brise Pharmaceuticals

AbbVie has agreed to pay up to $757m for rights to two migraine drugs from Brise Pharmaceuticals. Brise will handle discovery, while AbbVie manages development and commercialization. The deal includes milestone payments and potential royalties. Brise's CEO called it a validation of their research platform. The migraine market was valued at $17.2bn in 2023, with unmet treatment needs.

$QUREMed

UniQure gets an FDA decision date; Teva scraps brain drug study

UniQure's Huntington's disease gene therapy application is under FDA review with a decision expected by May 1. Teva Pharmaceuticals halted a mid-stage study of emrusolmin for multiple system atrophy due to futility. Bright Minds Biosciences' antiseizure drug trial was partially halted by the FDA. Specific Biologics raised $35M in Series A funding for ALS therapy trials. CinRx Pharma and Graviton BioScience formed a joint venture to develop cardiovascular drugs.